ziftomenib
kura oncology
['leusm', 'manifest,(-manifest-2),(-manifest2),(-manifest 2),(-manifest-i),(-manifesti),(-manifest i)', 'ziftomenib']
#ash22 #leusm erba: zifto orr 40% in npm1m with 30% cr. orr 16.7% in kmt2ar with 5% cr. responses seen in emd. good data (esp npm1m) for monotherapy in pop with &gt;3 median prior therapies, will be interesting to see in combo therapy. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)